莲和医疗2023年年报

Contents 2 Biographical Details of Directors and Senior Management34 129 131 Five Year Financial Summary216 Corporate Information EXECUTIVE DIRECTORS Mr. Yuan Limin(Chief Executive Officer)Mr. Pang ZhenMr. Man Wai Lun INDEPENDENT NON-EXECUTIVE DIRECTORS Dr. Wang, Bruce XianliangDr. Zhao, Shawn Xiaohong AUDIT COMMITTEEDr. Wang, Bruce Xianliang(Chairman)Dr. Zhao, Shawn Xiaohong REMUNERATION COMMITTEEDr. Zhao, Shawn Xiaohong(Chairman)Dr. Wang, Bruce Xianliang NOMINATION COMMITTEEDr. Wang, Bruce Xianliang(Chairman)Mr. Man Wai Lun AUTHORISED REPRESENTATIVES Mr. Pang ZhenMs. Shum Ching Yee Jennifer COMPANY SECRETARYMs. Shum Ching Yee Jennifer 38223 AUDITOR ZHONGHUI ANDA CPA Limited23/F, Tower 2, Enterprise Square Five38 Wang Chiu RoadKowloon Bay, KowloonHong Kong Corporate Information PRINCIPAL BANKER Bank of Communications (Hong Kong) Limited Cricket Square, Hutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands REGISTERED OFFICE Cricket Square, Hutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands PRINCIPAL OFFICE IN HONG KONG Room 6307-08, 63rd FloorCentral Plaza18 Harbour RoadWanchaiHong Kong 18636307-08 www.lifehealthcare.com COMPANY’S WEBSITEwww.lifehealthcare.com CAYMAN ISLANDS PRINCIPAL SHAREREGISTRAR AND TRANSFER OFFICE Suntera (Cayman) LimitedSuite 3204, Unit 2A, Block 3,Building D, P.O. Box 1586,Gardenia Cour t, Camana Bay,Grand Cayman, KY1-1100,Cayman Islands Suntera (Cayman) LimitedSuite 3204, Unit 2A, Block 3,Building D, P.O. Box 1586,Gardenia Cour t, Camana Bay,Grand Cayman, KY1-1100,Cayman Islands HONG KONG BRANCH SHARE REGISTRARAND TRANSFER OFFICE 1617 Tricor Tengis Limited17/F, Far East Finance Centre16 Harcour t RoadHong Kong 00928 LISTING INFORMATION The Stock Exchange of Hong Kong LimitedStock Code: 00928 Management Discussion and Analysis On behalf of Life Healthcare Group Limited (the “Company”), I presenttothe shareholders the results of the Company and its subsidiaries(collectively referred to as the “Group”) for the year ended 31 March2023. OVERVIEW TheGroup is a provider of genetic testing and health data analysisser vices.Through its non-invasive tumor genetic testing technologyand professional team, the Group is committed to the promotion andapplication of genetic testing in clinical medicine and related healthcareservices. In order to provide the public with easily available, convenient,high-quality and affordable medical and health products and services, theCompany has continued to deepen its medical testing business while alsoexpanding the sales of medical and health supplies, Internet medical dataservices and other emerging businesses, so as to create more value for theshareholders of the Company. The Group owns one medical and healthcare service and product salescentre in Yangzhou, with a business operation license of medical devices,which allows the Group to organize and perform the operation, salesand impor t and expor t of special medical products, as well as providehealthcareservices to customers across the country and around theworld. To complement the Group’s mature early cancer detection by genetictestingbusiness,the Company now also offers p-hydroxyphenylalanine() test on the patient’s urine using chemical colorimetricmethod to early detect cancer tumors. This chemical testing method canearly detect different types of cancer such as gastric cancer, esophagealcancer, and pancreatic cancer. Management Discussion and Analysis After multiple promoting methods, the Group has currently star ted tosell p-hydroxyphenylalanine urine testing products throughout China. Itsturnover has reached millions of Hong Kong dollars. The Group remainsto expand the sales channels of the products to more cities across thecountry to fur ther widen the sales network of the Group’s product. The Company, through its subsidiaries, provides medical supplies includingmedicalthermometers,masks,protective clothing,disinfectant,virustesting kits and reagents, breathing machines and other medical products,and also provides value-added services in respect of the procurement ofsuch medical supplies and products including providing market intelligence,sourcing of bids, comparative assessment of technical specifications andcost analysis, and negotiation of terms of supply. Dueto the frequent occurrence of regional COVID-19 pandemic,theGroup’s genetic testing business and expor t business were restricted, andthe Group is committed to developing domestic healthcare equipmentservicebusiness.Taking advantage of its own advantages,the Groupintegrateshealth data analysis software and healthcare equipment toprovide new healthcare services and products business, which has beenrecognized by the industry. The Group also expands its business to tradingof hygiene products to ride on the demand for personal and householdhygiene due to the growing awareness among consumers in the wake ofthe COVID-19 pandemic. The Group continues to expand its genetic testing